Comparing three treatments for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial compares three different treatment combinations for advanced stomach cancer that hasn't spread to the brain and is HER2-negative. It includes an immunotherapy drug (sintilimab) with different chemotherapy backbones, and one option adds a targeted therapy (lenvatinib). The goal is to see which combination works best and has acceptable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a confirmed diagnosis of stomach cancer (adenocarcinoma) that has spread to other parts of the body.
- The cancer must be HER2-negative and not MSI-high.
- You should be newly diagnosed, or have a recurrence at least 6 months after finishing adjuvant chemotherapy.
- You must be able to perform daily activities (ECOG score 0-1).
- Your organs (liver, kidneys, blood) must be functioning well enough, and you must not have major health issues like active infections or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two newer drugs (pucotenlimab and lenvatinib) to standard chemotherapy (SOX) works better than chemotherapy alone for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if the combination slows cancer growth.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and chemotherapy (FOLFIRI) for people with advanced stomach cancer that has not responded to first treatment. It aims to see if this combination can help control the cancer.
This trial tests a combination of three drugs — an immunotherapy (sintilimab), a targeted therapy (bevacizumab), and chemotherapy — for a specific type of stomach cancer that produces high AFP and has spread to the liver. The goal is to see if this treatment can shrink tumors enough to make them removable by surgery.
Hear when a new Gastric (Stomach) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.